.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,427,448

« Back to Dashboard

Details for Patent: 9,427,448

Title:Methods of treating, reducing the incidence of, and/or preventing ischemic events
Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y.sub.12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
Inventor(s): Arculus-Meanwell; Clive Arthur (Bernardsville, NJ), Skerjanec; Simona (Basel, CH), Prats; Jayne (Carlisle, MA)
Assignee: The Medicines Company (Parsippany, NJ)
Filing Date:Mar 09, 2013
Application Number:13/792,056
Claims:1. A method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor; wherein the pharmaceutical composition is administered intravenously as a 30 .mu.g/kg bolus before the start of PCI, and then is administered intravenously as a continuous infusion at an infusion rate of 4 .mu.g/kg/min after administration of the bolus for the longer of (a) at least two hours or (b) the duration of the PCI.

2. The method of claim 1, wherein the method treats, reduces the incidence of, or prevents an ischemic event during PCI.

3. The method of claim 1, wherein the method treats, reduces the incidence of, or prevents an ischemic event after PCI.

4. The method of claim 1, wherein the ischemic event is selected from the group consisting of stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.

5. The method of claim 4, wherein the ischemic event is stent thrombosis.

6. The method of claim 5, wherein the stent thrombosis is intraprocedural stent thrombosis.

7. The method of claim 1, wherein the administration of the pharmaceutical composition to the patient is not accompanied by a significant increase in severe bleeding or the need for transfusions.

8. The method of claim 1, wherein the PCI comprises stent implantation.

9. A method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing PCI, comprising administering to the patient (i) a pharmaceutical composition comprising cangrelor, and (ii) a P2Y.sub.12 inhibitor; wherein the pharmaceutical composition is administered intravenously as a 30 .mu.g/kg bolus before the start of PCI, and then is administered intravenously as a continuous infusion at an infusion rate of 4 .mu.g/kg/min after administration of the bolus for the longer of (a) at least two hours or (b) the duration of the PCI.

10. The method of claim 9, wherein the method treats, reduces the incidence of, or prevents an ischemic event during PCI.

11. The method of claim 9, wherein the method treats, reduces the incidence of, or prevents an ischemic event after PCI.

12. The method of claim 9, wherein the P2Y.sub.12 inhibitor is selected from the group consisting of clopidogrel, prasugrel, and ticagrelor.

13. The method of claim 12, wherein the P2Y.sub.12 inhibitor is clopidogrel.

14. The method of claim 13, wherein the clopidogrel is administered after administration of the pharmaceutical composition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc